Dr. Milos joined SeqLL’s board in Aug 2021 as an independent director, having also served as a consultant and scientific advisor to our management team since our inception. Since September 2020, Dr. Milos has been Vice President, Scientific Operations of Proof Diagnostics, (formerly Pine Trees Health, Inc.), a company that is developing a low-cost, rapid diagnostic testing platform for the detection of COVID-19. Dr. Milos was a co-founder, President and Chief Executive Officer of Medley-Genomics Inc., a company focused on using advanced data analytics to support better diagnosis and treatment of complex diseases. From May 2013 to January 2016, Dr. Milos was President and Chief Executive Officer of Claritas Genomics Inc., a subsidiary of Boston Children’s Hospital that provided commercial next-generation pediatric molecular diagnostic testing. Dr. Milos is also a member of the board of directors of 54Gene Inc, Slater Technology Fund and RI Bio. Dr. Milos has received numerous awards and honors within the life sciences industry and has authored or co-authored over 40 biotech or life sciences publications.

Dr. Milos earned a B.A. in biology and chemistry from The College of Saint Rose, a M.S. and Ph.D. in plant molecular genetics and biology from Rensselaer Polytechnic Institute and has completed Post-Doctoral work at Harvard University and Brown University in plant and mouse molecular genetics.